metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-89 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN LIVER TRANSPLANT PATIENTS: FACTOR...
Journal Information
Vol. 29. Issue S3.
Abstracts of the 2024 Annual Meeting of the ALEH
(December 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S3.
Abstracts of the 2024 Annual Meeting of the ALEH
(December 2024)
Full text access
P-89 ADHERENCE TO IMMUNOSUPPRESSIVE THERAPY IN LIVER TRANSPLANT PATIENTS: FACTORS ASSOCIATED TO COMPLIANCE AND IMPACT ON QUALITY OF LIFE
Visits
30
Carol Roa1, Daniela Simian2, Matías Martínez1, Vicente Arancibia1, Jaime Poniachik2
1 Departamento de Ciencias y Tecnología Farmacéuticas, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile
2 Hospital Clínico Universidad de Chile, Santiago, Chile
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (1)
Special issue
This article is part of special issue:
Vol. 29. Issue S3

Abstracts of the 2024 Annual Meeting of the ALEH

More info
Conflict of interest

No

Introduction and Objectives

One of the primary challenges following liver transplantation is preventing graft rejection, for which immunosuppressive therapy is essential. The success of this therapy depends, among other factors, on patient adherence to the prescribed medication regimen. The aim was to evaluate adherence to immunosuppressive therapy and the possible factors associated to adherence in liver transplant patients.

Patients / Materials and Methods

This is an analytical, observational, cross-sectional study conducted with liver transplant patients between 2004 and 2023 at Hospital Clínico Universidad de Chile. Participants were required to complete two self-administered questionnaires: the "Simplified Medication Adherence Questionnaire" (SMAQ) to assess adherence (classified as adherent or non-adherent) and the "European Quality of Life-5 Dimensions" (EQ-5D) to assess quality of life. Additionally, a form was used to collect sociodemographic and clinical data, supplemented with information from the hospital's medical records. All data were recorded using the REDCap® platform.

Results and Discussion

The study included 29 patients with a median post-transplant follow-up of 37 months (range: 1 – 237 months). Of these patients, 41% (12 patients) were identified as non-adherent to immunosuppressive therapy, with occasional forgetfulness being the primary cause. Analysis revealed that younger patients, those with less comorbidity, and those with a longer time since transplantation were less adherent to the therapy. Tacrolimus was the most commonly used drug, and no significant differences in adherence were found based on the type of immunosuppressant used. Adherent patients reported a better quality of life compared to non-adherent patients.

Conclusions

A significant proportion of liver transplant patients exhibit non-adherence to immunosuppressive therapy. Factors such as medication forgetfulness, time since transplantation, and the presence of chronic illnesses impact adherence. It is recommended to enhance patient-provider relationships, regularly assess adherence, and provide patient education to improve quality of life and minimize the risk of graft rejection.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos